Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Ultragenyx Shares Increase 30% on Results from Phase 1/2 OTC Deficiency Study

Rare disease biopharmaceutical company Ultragenyx Pharmaceutical's shares traded 30% higher after the firm reported positive topline results from Cohorts 2 and 3 in its Phase 1/2 study of DTX301 gene therapy in Ornithine Transcarbamylase Deficiency. After U.S. markets...
Streetwise Reports | January 13, 2020 |

Burcon NutraScience, Saturn Oil & Gas, Very Good Food - good Canadian companies with potential

Canada is a country with many creative and enterprising people. Metropolises such as Toronto and Vancouver offer a lot of potential for new business ideas. But also, in cities of the provinces many entrepreneurs start their adventures and want to improve the world. Canadian Pr...
Mario Hose | June 25, 2020 |

HAVN Life Sciences: Using psychedelics, specifically mushrooms, to improve mental health

Mental health, as we know, controls a large part of how we interact with the world around us. Our next guest knows this and is working to improve the mental health of those struggling by using psychedelics, specifically mushrooms. Psychedelics are not federally l...
Brieanna McCutcheon | November 4, 2022 |

A Splendid Investment Opportunity…Naturally

(Click image to play video) We’re just about smackdab in the middle of New Year’s resolution time, and millions of North Americans are committing to a healthier lifestyle or just trying to shed a few pounds. Coquitlam, BC-based...
Dave Jackson | January 22, 2021 |

Arcadia Ropes in $3 Million in GoodHemp Seed Purchase Orders Within 50 Days of Product Launch

Arcadia Biosciences shares traded 25% higher after reporting that it secured $3 million in pre-season GoodHemp seed purchase commitments in just 50 days after launching the product. Arcadia Biosciences Inc. (RKDA:NASDAQ) , which employs science-based approac...
Streetwise Reports | January 31, 2020 |

Buzz on the Bullboards: Upbeat U.S. earnings good news for all?

Do rising tides truly lift all ships? We are in the midst of a strong earnings season and U.S. markets have reacted in kind. Strong earnings growth pushed Wall Street indices towards fresh record highs this past week. While activity moved lower earlier on, the belief ...
Jonathon Brown | February 8, 2024 |

Fibrocell Science Shares Rise 60% on Acquisition News

Fibrocell Science's shares are trading up 60% today after the company announced that it agreed to be acquired by Castle Creek Holdings for $63.3 million, or $3.00 per share. Cell and gene therapy company Fibrocell Science Inc. (FCSC:NASDAQ) , which focuses on transfo...
Streetwise Reports | September 16, 2019 |

Ovid Therapeutics Posts Positive Data from Phase 2 Seizure Reduction Trial

Ovid Therapeutics' shares are trading 25% higher today after the company reported positive initial data from its ENDYMION soticlestat phase 2 trial for patients with developmental and epileptic encephalopathies. Shares of Ovid Therapeutics Inc. (OVID:NASDAQ) are tra...
Streetwise Reports | September 25, 2019 |

Marinus Pharma Shares Open Up 41% on Phase 2 Epilepsy Trial Results

Marinus Pharmaceuticals reported positive top-line results for ganaxolone in its Phase 2 refractory status epilepticus trial with all patients achieving the primary endpoint. This morning Marinus Pharmaceuticals Inc. (MRNS:NASDAQ) , a pharmaceutical firm dedicated to...
Streetwise Reports | September 27, 2019 |

ChemoCentryx Shares Spike 300% on Phase 3 ANCA Vasculitis Trial Results

Shares of ChemoCentryx Inc. opened greater than 330% higher today after the firm reported positive topline data from its pivotal Phase 3 ADVOCATE trial of Avacopan in treatment of ANCA-associated vasculitis. After the U.S. markets closed yesterday, ChemoCentryx Inc. ...
Streetwise Reports | November 27, 2019 |
1 2 3